Philip J. Rosenfeld

About Philip J. Rosenfeld

What is the most exciting thing happening in retina right now? And can you make a bold prediction for the future of retina treatment?

These two questions are intertwined. The most exciting advances in retina involve the use of artificial intelligence (AI), particularly machine learning, to develop diagnostic algorithms that enhance our interpretation of retinal images so that we can better predict disease progression. The future of retinal treatments will directly impact our ability to apply these improved retinal imaging algorithms to clinical trials. We’ll be able to define new clinical trial endpoints that allow us to treat earlier and get results faster. OCT imaging will be the greatest beneficiary of these improving algorithms with the greatest impact being felt in age-related macular degeneration and diabetic retinopathy. I am particularly excited about the future of OCT imaging in age-related macular degeneration (AMD) and our ability to identify early disease biomarkers that can be targeted with novel therapies so that more vision can be preserved.

What advice would you give to your younger self?

I’d encourage myself to follow my instincts to focus on the most important unanswered questions, always question dogma, and have confidence in my clinical and research judgments.